Balyasny Asset Management LLC Gilead Sciences, Inc. Call Options Transaction History

Balyasny Asset Management LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $1.46 Million - $1.85 Million	22,000 Added 628.57%	25,500 $2.14 Million
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $4.43 Million - $5.11 Million	-70,100 Reduced 95.24%	3,500 $240,000
Q1 2024 May 13, 2024	SELL	$71.58 - $87.29 $372,216 - $453,908	-5,200 Reduced 6.6%	73,600 $5.39 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $3.09 Million - $3.51 Million	-42,200 Reduced 34.88%	78,800 $6.38 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $2.44 Million - $3.51 Million	-39,200 Reduced 24.47%	121,000 $10.4 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $6.45 Million - $7.37 Million	108,300 Added 208.67%	160,200 $9.88 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $3 Million - $3.37 Million	51,900 New	51,900 $3.21 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $771,666 - $832,542	-11,400 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $6.89 Million - $7.52 Million	-108,500 Reduced 90.49%	11,400 $785,000
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $7.45 Million - $9.36 Million	119,900 New	119,900 $7.58 Million

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.